Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

East Melbourne, Australia Clinical Trials

A listing of East Melbourne, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (193) clinical trials

Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

Macular edema (ME) is the most common structural complication and cause of visual impairment and legal blindness in uveitis patients. Traditional approaches to the treatment of uveitic ME have included the use of regional corticosteroid therapy, delivered periocularly, including posterior sub-Tenon's and orbital floor injections, or via the intravitreal route. …

Phase

0.0 miles

Learn More »

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Abstract from protocol: The uveitides are a collection of diseases characterized by intraocular inflammation. Collectively, they are the 5th leading cause of blindness in the US, and the estimated cost of treating them is similar to that of treating diabetic retinopathy. Non-infectious intermediate, posterior, and panuveitides have the highest rates …

Phase

0.0 miles

Learn More »

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Primary Objective: To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously To determine the incidence of anti-blinatumomab antibody formation following SC administration …

Phase

0.33 miles

Learn More »

A Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the Renexus implants in participants with macular telangiectasia type 2.

Phase

0.33 miles

Learn More »

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in approximately 471 patients with moderate to severe HS. The study consists of: screening (up to 4 weeks) treatment period 1 (16 weeks, active drug or placebo) and treatment period 2 (up to 1 year …

Phase

0.33 miles

Learn More »

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Phase

0.33 miles

Learn More »

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.

Phase

0.33 miles

Learn More »

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent patients age 12 years and above, weighing at least 40 kg, with moderate to severe atopic dermatitis.

Phase

0.33 miles

Learn More »

A Study Assessing the Efficacy and Safety of CBP-201

This is a randomized, double-blind, placebo-controlled, dose regimen finding study to assess the efficacy, safety, and steady-state PK profile of CBP-201 administered to eligible adult subjects with moderate to severe atopic dermatitis compared to placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into a treatment …

Phase

0.33 miles

Learn More »

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to evaluate the long-term safety and efficacy of lebrikizumab in participants with moderate-to-severe atopic dermatitis.

Phase

0.33 miles

Learn More »